What is Leede Financial’s Estimate for THTX FY2025 Earnings?

Theratechnologies Inc. (NASDAQ:THTX) – Research analysts at Leede Financial lowered their FY2025 earnings estimates for shares of Theratechnologies in a research report issued to clients and investors on Wednesday, February 26th. Leede Financial analyst D. Loe now expects that the company will earn $0.06 per share for the year, down from their previous forecast of $0.07. The consensus estimate for Theratechnologies’ current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies’ FY2026 earnings at $0.15 EPS.

Separately, Research Capitl upgraded Theratechnologies to a “strong-buy” rating in a report on Friday, February 14th.

Theratechnologies Stock Performance

Theratechnologies stock opened at $1.60 on Thursday. Theratechnologies has a 52 week low of $1.08 and a 52 week high of $2.18. The firm has a market cap of $73.57 million, a P/E ratio of -16.00 and a beta of 1.26. The business’s fifty day moving average is $1.74 and its two-hundred day moving average is $1.45.

Institutional Trading of Theratechnologies

A number of institutional investors and hedge funds have recently modified their holdings of THTX. Raymond James Financial Inc. bought a new stake in shares of Theratechnologies in the 4th quarter valued at $27,000. Bank of America Corp DE lifted its stake in Theratechnologies by 1,416.7% in the 4th quarter. Bank of America Corp DE now owns 16,487 shares of the company’s stock valued at $30,000 after acquiring an additional 15,400 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of Theratechnologies in the fourth quarter valued at approximately $33,000. BNP Paribas Financial Markets acquired a new position in Theratechnologies during the fourth quarter worth $36,000. Finally, Virtu Financial LLC acquired a new stake in Theratechnologies in the 4th quarter valued at $40,000.

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.